Nisa Investment Advisors LLC Sells 12,392 Shares of Hologic, Inc. $HOLX

Nisa Investment Advisors LLC lowered its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 27.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,806 shares of the medical equipment provider’s stock after selling 12,392 shares during the period. Nisa Investment Advisors LLC’s holdings in Hologic were worth $2,444,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. The Manufacturers Life Insurance Company lifted its holdings in shares of Hologic by 294.3% during the second quarter. The Manufacturers Life Insurance Company now owns 11,022,455 shares of the medical equipment provider’s stock valued at $718,223,000 after purchasing an additional 8,227,318 shares during the last quarter. Invesco Ltd. grew its stake in shares of Hologic by 72.5% in the 2nd quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider’s stock worth $543,486,000 after buying an additional 3,505,828 shares during the last quarter. Balyasny Asset Management L.P. increased its position in Hologic by 1,060.1% during the 3rd quarter. Balyasny Asset Management L.P. now owns 1,218,352 shares of the medical equipment provider’s stock valued at $82,227,000 after buying an additional 1,113,330 shares in the last quarter. Adage Capital Partners GP L.L.C. bought a new position in Hologic during the 2nd quarter valued at approximately $48,283,000. Finally, Freestone Grove Partners LP purchased a new position in Hologic during the third quarter valued at $46,800,000. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Price Performance

Hologic stock opened at $75.65 on Friday. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $75.78. The stock has a fifty day simple moving average of $75.28 and a two-hundred day simple moving average of $73.60. The company has a current ratio of 4.04, a quick ratio of 3.32 and a debt-to-equity ratio of 0.48. The firm has a market cap of $16.89 billion, a price-to-earnings ratio of 31.52, a PEG ratio of 2.24 and a beta of 0.70.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). Hologic had a net margin of 13.18% and a return on equity of 19.58%. The business had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the previous year, the company earned $0.87 earnings per share. The company’s revenue for the quarter was up 2.5% compared to the same quarter last year. Equities analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Argus cut Hologic from a “buy” rating to a “hold” rating in a research note on Monday, January 12th. Evercore cut shares of Hologic from an “outperform” rating to an “in-line” rating and dropped their price target for the stock from $79.00 to $78.00 in a research note on Monday, January 5th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Hologic in a research report on Wednesday, January 28th. Two investment analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the stock. Based on data from MarketBeat, Hologic currently has a consensus rating of “Hold” and a consensus price target of $78.42.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.